Evidence map›Paper›PMID 37764342›Full record

ArticleMolecules (Basel, Switzerland)2023

Emodin as an Inhibitor of PRV Infection In Vitro and In Vivo.

Xiaojing Cai, Zhiying Wang, Xiaocheng Li, Jing Zhang, Zhiyuan Ren, Yi Shao, Yongkang Xu, Yan Zhu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Evasion of the Antiviral Innate Immunity by PRV.International journal of molecular sciences · 2024
    Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiaojing CaiCollege of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
Zhiying WangCollege of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.ORCID 0009-0006-0922-6382
Xiaocheng LiHarbin Da BEINONG Animal Husbandry Technology Co., Ltd., Harbin 150030, China.
Jing ZhangHarbin Da BEINONG Animal Husbandry Technology Co., Ltd., Harbin 150030, China.
Zhiyuan RenCollege of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
Yi ShaoCollege of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
Yongkang XuCollege of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
Yan ZhuCollege of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China.
Northeast Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudorabies (PR) is an acute and severe infectious disease caused by pseudorabies virus (PRV). Once the virus infects pigs, it is difficult to eliminate, resulting in major economic losses to the global pig industry. In addition, reports of human infection with PRV suggest that the virus is a potential threat to human health; thus, its significance to public health should be considered. In this paper, the anti-PRV activities of emodin in vitro and in vivo, and its mechanism of action were studied. The results showed that emodin inhibited the proliferation of PRV in PK15 cells in a dose-dependent manner, with an IC50 of 0.127 mg/mL and a selection index of 5.52. The addition of emodin at different stages of viral infection showed that emodin inhibited intracellular replication. Emodin significantly inhibited the expression of the IE180, EP0, UL29, UL44, US6, and UL27 genes of PRV within 48 h. Emodin also significantly inhibited the expression of PRV gB and gD proteins. The molecular docking results suggested that emodin might form hydrogen bonds with PRV gB and gD proteins and affect the structure of viral proteins. Emodin effectively inhibited the apoptosis induced by PRV infection. Moreover, emodin showed a good protective effect on PRV-infected mice. During the experimental period, all the control PRV-infected mice died resulting in a survival rate of 0%, while the survival rate of emodin-treated mice was 28.5%. Emodin also significantly inhibited the replication of PRV in the heart, liver, brain, kidneys and lungs of mice and alleviated tissue and organ damage caused by PRV infection. Emodin was able to combat viral infection by regulating the levels of the cytokines TNF-α, IFN-γ, IL-6, and IL-4 in the sera of infected mice. These results indicate that emodin has good anti-PRV activity in vitro and in vivo, and is expected to be a new agent for the prevention and control of PRV infection.

Indexed as

EmodinHerpesvirus 1, SuidPseudorabiesAnimalsApoptosisHumansMolecular Docking SimulationSwineEmodinantiviralemodinpseudorabies virus

Identifiers

PMID37764342
PMCPMC10537396
OpenAlexW4386602478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.